What is this study trying to find out about plasma cell disorders?

This study aims to understand the clinical features and treatment responses of various plasma cell disorders. Researchers are focusing on how minimal residual disease status relates to patient outcomes and the role of the tumor environment in disease progression. The study is led by Peking University First Hospital to improve knowledge of these disorders.

Who may be eligible for this plasma cell disorder clinical trial?

Adults with confirmed plasma cell disorders who are hospitalized at Peking University First Hospital and willing to sign consent may be eligible. There are no gender or age restrictions stated, but significant life-threatening conditions may exclude participation. Please review eligibility criteria for more details.

Is there any cost to participate in this plasma cell disorder clinical trial?

Study-related care, including all trial visits and sample collection, is provided at no cost. However, personal expenses such as travel or accommodation may vary and are not guaranteed to be covered.

Actively Recruiting

All Genders

Healthy Volunteers

ID05283993

A Prospective Study to Follow Patients with Plasma Cell Disorders at Peking University First Hospital

Led by Peking University First Hospital · Updated on 2022-04-25

2000

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are establishing a prospective group of patients with plasma cell disorders PCDs to better understand these conditions and their treatments. This study focuses on various PCDs including multiple myeloma, amyloidosis, and other related disorders. It aims to explore how minimal residual disease MRD status relates to patient prognosis and investigate the role of the tumor microenvironment TME in the diseases development and progression. Patients with confirmed PCDs who are hospitalized and willing to participate will be followed over time. Biological samples such as peripheral blood, bone marrow aspirate, and urine will be collected before and after treatment to support future research. The study does not involve any intervention and participants will be regularly assessed at baseline, then at 1, 3, 6, and 12 months after treatment, followed by yearly visits. During the study, clinical and laboratory data along with biological samples will be gathered to analyze disease features and treatment responses. Follow-up visits will monitor patient progress and outcomes for up to ten years. The main outcome is to maintain a comprehensive cohort and understand the relationship between MRD and prognosis in PCD patients, while also supporting further studies on tumor clone evolution and disease mechanisms.

CONDITIONS

Brief Title

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

Who Can Participate

All Genders

Healthy Volunteers

Eligibility Criteria

You may qualify if you...

Patients with a confirmed diagnosis of plasma cell disorders (PCDs) hospitalized at Peking University First Hospital
Patients diagnosed with any of the following: monoclonal gammopathy of uncertain significance, smoldering myeloma, multiple myeloma, plasma cell leukemia, amyloidosis, light chain deposition disease, heavy chain deposition disease, Castleman's disease, POEMS syndrome, cryoglobulinemia, monoclonal gammopathy of renal significance, or monoclonal gammopathy of neurological significance
Willingness to sign the informed consent form (ICF) to participate

You will not qualify if you...

Presence of significant life-threatening comorbidities

Research Team

Bo Tang, PhD

Yujun Dong, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here